JP2019513775A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513775A5
JP2019513775A5 JP2018553445A JP2018553445A JP2019513775A5 JP 2019513775 A5 JP2019513775 A5 JP 2019513775A5 JP 2018553445 A JP2018553445 A JP 2018553445A JP 2018553445 A JP2018553445 A JP 2018553445A JP 2019513775 A5 JP2019513775 A5 JP 2019513775A5
Authority
JP
Japan
Prior art keywords
composition
selenium
amino acid
containing amino
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018553445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513775A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000638 external-priority patent/WO2017182885A2/en
Publication of JP2019513775A publication Critical patent/JP2019513775A/ja
Publication of JP2019513775A5 publication Critical patent/JP2019513775A5/ja
Pending legal-status Critical Current

Links

JP2018553445A 2016-04-19 2017-04-18 角化症の処置のための組成物 Pending JP2019513775A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324795P 2016-04-19 2016-04-19
US62/324,795 2016-04-19
PCT/IB2017/000638 WO2017182885A2 (en) 2016-04-19 2017-04-18 Compositions for the treatment of hyperkeratosis disorders

Publications (2)

Publication Number Publication Date
JP2019513775A JP2019513775A (ja) 2019-05-30
JP2019513775A5 true JP2019513775A5 (enExample) 2020-06-18

Family

ID=60115757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553445A Pending JP2019513775A (ja) 2016-04-19 2017-04-18 角化症の処置のための組成物

Country Status (10)

Country Link
US (2) US20200179305A1 (enExample)
EP (1) EP3445352A4 (enExample)
JP (1) JP2019513775A (enExample)
KR (1) KR20180133913A (enExample)
CN (1) CN109328061A (enExample)
AU (1) AU2017252026A1 (enExample)
CA (1) CA3020713A1 (enExample)
IL (1) IL262348A (enExample)
MA (1) MA44737A (enExample)
WO (1) WO2017182885A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
EP3313413B1 (en) 2015-09-28 2024-12-04 Azura Ophthalmics Ltd Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
BR112018070852B1 (pt) * 2016-04-14 2024-01-16 Azura Ophthalmics Ltd Composições de dissulfeto de selênio
CA3040453A1 (en) 2016-10-12 2018-04-19 Jds Therapeutics, Llc Heavy-metal-free magnesium picolinate compositions for enhancing the bioavailability of magnesium and picolinic acid
CN108840904B (zh) * 2018-07-12 2022-03-04 江西中科硒谷功能农业发展有限公司 一种从烟叶中提取硒蛋白质的方法
JP7142286B2 (ja) * 2018-07-13 2022-09-27 慶應義塾 セレン含有アミノ酸を含む糖鎖-ポリペプチド複合体、および、その医薬用途
CA3137583A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CN114025759A (zh) 2019-04-18 2022-02-08 阿祖拉眼科有限公司 用于治疗眼病的化合物和方法
KR20210154214A (ko) 2019-04-18 2021-12-20 아주라 오프탈믹스 엘티디 안구 질병의 치료를 위한 화합물 및 방법
US20200345768A1 (en) * 2019-05-01 2020-11-05 Nutrition 21, Llc Zinc picolinate, magnesium picolinate and selenium methionine compositions and methods of use
WO2021140417A2 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity
MX2023004538A (es) * 2020-10-21 2023-06-19 Azura Ophthalmics Ltd Compuestos y metodos para el tratamiento de trastornos oculares.
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
US6495158B1 (en) * 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
US20030224028A1 (en) * 2002-05-13 2003-12-04 Societe L'oreal S.A. Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
WO2005079143A2 (en) * 2004-02-19 2005-09-01 Occell Inc. Topical formulations for the treatment of skin conditions
ES2422893T3 (es) * 2004-08-02 2013-09-16 Sami Labs Limited Composiciones y procedimientos para el tratamiento de las afecciones dermatológicas hiperproliferativas
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
RU2008102249A (ru) * 2005-06-22 2009-07-27 Кова Компани, Лтд. (Jp) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
KR20120093932A (ko) * 2009-10-10 2012-08-23 일레븐 바이오테라피틱스, 아이엔씨. Il-17 패밀리 사이토카인 조성물들 및 용도들
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2014094918A1 (en) * 2012-12-21 2014-06-26 Aqua Bio Technology Asa Cosmetic compositions from fish hatching fluid
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction

Similar Documents

Publication Publication Date Title
JP2019513775A5 (enExample)
ES2456502T3 (es) Composición que comprende PNC o PNB para un preparado externo para la piel para el tratamiento de la dermatitis
WO2017182885A3 (en) Compositions for the treatment of hyperkeratosis disorders
ES2958621T3 (es) Composiciones para el tratamiento tópico de infecciones microbianas
JP2011116787A5 (enExample)
JP2016540785A5 (enExample)
RU2015122627A (ru) Кожные композиции, содержащие неприродные гигроскопические аминокислоты
BR112020008077A2 (pt) composição farmacêutica, composição farmacêutica para aplicação tópica e uso de uma composição tópica
ES2289527T3 (es) Uso de una composicion reestructurante de uñas para aplicacion topica en onicosquisis.
JP2018528259A5 (enExample)
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
BR112015027992A2 (pt) uso de ácido petroselínico para combater desordens estéticas da figura do corpo
JPWO2022138842A5 (enExample)
CN102105142A (zh) 用于治疗红斑狼疮的包括壳聚糖和二羧酸的组合物
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
WO2014204357A3 (ru) Лекарственное средство для лечения кератоконуса
RU2012130852A (ru) Фармацевтическая композиция для местного применения при лечении воспалительных заболеваний глаз и способ ее использования
JP2004107242A (ja) 乾燥肌改善用キット
ES2641561T3 (es) Sistema a base de magnesio y su uso en cosmética
RU2009132576A (ru) Улучшенная композиция для местного переноса активных компонентов в организм человека или животных
JPWO2022138826A5 (enExample)
ES2542629T3 (es) Composiciones farmacéuticas y aplicaciones terapéuticas de un derivado de hidrocortisona designado como Deina
JP2012206961A (ja) 抗菌剤及び皮膚外用剤
US11672769B2 (en) Paraffin wax with CBD isolate
JP6558117B2 (ja) 皮膚用剤